Celling Biosciences

Celling Biosciences is a private medical device company operating in the rapidly growing field of point-of-care regenerative medicine. Its core business revolves around a proprietary platform of FDA-approved devices that enable physicians to process a patient's bone marrow or blood into concentrated cellular therapies during a single office visit. The company targets a broad clinical market through a distributor network, supporting over 1,000 physician providers and claiming more than 100,000 procedures performed. Its strategy integrates product development with physician education and marketing support to drive adoption in an emerging therapeutic area.

Integrated point-of-care platform for autologous tissue processing. Includes devices for bone marrow/blood aspiration (Cell Probe 360), concentration via patented ultrafiltration (ART PLUS family), and delivery. Technology enables bedside processing of Bone Marrow Concentrate (BMC) and Platelet-Rich Plasma (PRP).

Celling operates in a competitive point-of-care cell concentration device market with players like Harvest Technologies (Terumo), Arthrex, and EmCyte. Its differentiation is based on its integrated ultrafiltration system and patented cell selection window. The broader competitive field includes pharmaceutical companies developing allogeneic cell therapies and other biotechs focused on more advanced engineered tissues.